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Antibiotic resistance determination of Ureaplasma spp. (Ureaplasma parvum and Ureaplasma urealyticum)
usually requires predetermination of bacterial titer, followed by antibiotic interrogation using a set bacterial
input. This 96-well method allows simultaneous quantification of bacteria in the presence and absence of
antibiotics. A method for determining precise MICs and a method for screening against multiple antibiotics
using breakpoint thresholds are detailed. Of the 61 Ureaplasma-positive clinical isolates screened, one (1.6%)
was resistant to erythromycin (MIC, >64 mg/liter) and clarithromycin (MIC, 4 mg/liter), one to ciprofloxacin
(1.6%), and one to tetracycline/doxycycline (1.6%). Five isolates were also consistently found to have an elevated
MIC of 8 mg/liter for erythromycin, but this may not represent true antibiotic resistance, as no mutations were
found in the 23S rRNA operons or ribosome-associated L4 and L22 proteins for these strains. However, two
amino acids (R66Q67) were deleted from the L4 protein of the erythromycin-/clarithromycin-resistant strain.
The tetM genetic element was detected in the tetracycline-resistant clinical isolate as well as in the positive
control Vancouver strain serotype 9. The tetM gene was also found in a fully tetracycline-susceptible Urea-
plasma clinical isolate, and no mutations were found in the coding region that would explain its failure to
mediate tetracycline resistance. An amino acid substitution (D82N) was found in the ParC subunit of the
ciprofloxacin-resistant isolate, adjacent to the S83L mutation reported by other investigators in many cipro-
floxacin-resistant Ureaplasma isolates. It is now possible to detect antibiotic resistance in Ureaplasma within
48 h of positive culture without prior knowledge of bacterial load, identifying them for further molecular
analysis.
Ureaplasmas and mycoplasmas are eubacteria belonging to
the class Mollicutes. These unique organisms are the smallest
self-replicating cells that lack a cell wall. Lack of a rigid cell
wall prevents reactivity with Gram staining and makes them
insusceptible to antibiotics that target bacterial cell walls (i.e.,
-lactams and glycopeptides), while imparting a frailty that
mostly limits them to a parasitic existence in association with
the eukaryotic cells of their host (39). Shepard first described
ureaplasmas, or T-mycoplasmas, in the 1950s, following isola-
tion from a male patient with nongonococcal urethritis (31).
This remains the most widely recognized patient group; how-
ever, they are also commonly found as commensals in the
genital tract in as many as 80% of women of child-bearing age
(30). Although the factors leading to intrauterine infection are
unclear, detection of Ureaplasma in the amniotic fluid is fre-
quently associated with chorioamnionitis, spontaneous abor-
tion, and premature birth (13, 14, 40). It has been suggested
that the rate of vertical transmission is inversely proportional
to gestational age at time of delivery (1). Furthermore, the
presence of Ureaplasma in the lungs of very premature neo-
nates has been associated with the development of chronic
lung disease (or bronchopulmonary dysplasia) and long-term
hospitalization (7, 19, 29, 30).
Ureaplasma spp. are susceptible to bacteriostatic agents such
as protein synthesis-inhibiting tetracyclines and macrolides as
well as bactericidal agents, including fluoroquinolones. For
premature neonatal patients, however, the removal of a mi-
crobe must be balanced against the potential (and often un-
known) toxicity of the antibiotics in these patients (38). For
this reason, physicians routinely favor macrolide antibiotics
such as erythromycin when deciding to treat Ureaplasma infec-
tions in premature neonates.
Only a limited number of reports have been made regarding
the trends in resistance among Ureaplasma isolates from neo-
nates (18, 34, 37), and all of these comment on the lack of a
standardized methodology, which hinders comparison of re-
sults. Factors such as inoculum size, pH of media, and time of
incubation are known to dramatically alter the MIC, and stan-
dardized means of detecting resistance are needed.
Here, we describe a modified breakpoint analysis in a 96-
well broth microdilution format that enables a concurrent de-
termination of bacterial load in a sample simultaneously with
the determination of resistance without prior knowledge of
bacterial load. For isolates showing resistance within the
breakpoint concentration, full MICs can be determined using a
similar full-plate methodology. The breakpoint method was
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used to screen 15 strains isolated during 2006 and 2007 from
bronchoalveolar lavage samples from neonates of various ges-
tational ages at the University Hospital of Wales (UHW),
Cardiff, United Kingdom, in addition to 46 frozen isolates from
a reference repository of samples submitted to the Health
Protection Agency at Colindale (London, United Kingdom)
from 2003 to present. Within these 61 isolates, we identified
one erythromycin-/clarithromycin-resistant, one ciprofloxacin-
resistant, and one tetracycline-resistant Ureaplasma strain.
Further PCR and sequence analyses were performed to deter-
mine the mechanism of resistance.
MATERIALS AND METHODS
USM and culture conditions. Ureaplasmas were grown in commercially avail-
able ureaplasma selective medium (USM) purchased from Mycoplasma Experi-
ence Ltd. (Surrey, United Kingdom). While the exact formula of the commer-
cially obtained medium is proprietary, the simple broth base medium was
supplemented with yeast extract, 1 g/liter urea, and 10% porcine serum, with
phenol red as the pH indicator (starting pH, 6.65) and with 2.5 g/ml ampho-
tericin B and 0.25 mg/ml ampicillin (neither of which inhibit the growth of
ureaplasmas). The adapted microbroth technique was carried out in flat-bottom
96-well plates covered with adhesive sealing tape (Elkay, Basingstoke, United
Kingdom) in a humidified tissue culture incubator set at an ambient CO2 con-
centration at 37°C. The sealing tape does not allow gas exchange, and the
humidified incubator ensures that the integrity of the outermost wells is the same
as those that are more central to the plate.
Sample collection. Bronchoalveolar lavage (BAL) samples were collected
from 20 preterm and term neonates requiring mechanical ventilation on the
neonatal ward at the UHW (Cardiff, United Kingdom). Samples were initially
screened for Ureaplasma infection by addition of 25 l BAL fluid to 2 ml USM
and incubation at 37°C for 1 week. Samples that turned a clear red color
(indicating Ureaplasma growth in the absence of contaminating bacteria) follow-
ing incubation were confirmed by PCR using the Ureaplasma-specific primers U4
and U5, which selectively amplify the urease gene (see below). Positive samples
were diluted 1:100 and 1:1,000 in USM, incubated overnight, divided into ali-
quots, and frozen at 80°C for later batch analysis. Fifteen clinical Ureaplasma
isolates were successfully archived at 80°C in USM and used for later suscep-
tibility testing. An additional 46 archived Ureaplasma isolates were revived from
a potential 77 samples submitted for testing to the Health Protection Agency
(HPA) at Colindale. The HPA clinical laboratory confirmed that no samples
used were contaminated with mycoplasma using specific culture methods. Known
serovar (SV) isolates used as reference strains were also obtained from HPA,
although SV1 (DKF-1) and SV9 (Vancouver isolate) were originally obtained
from the Institute of Medical Microbiology, University of Aarhus, Denmark.
Screening of HPA isolates using a modified breakpoint method. Erythromycin
was purchased from Sigma-Aldrich (Dorset, United Kingdom) as a 1-mg/ml
stock solution, while azithromycin, clarithromycin, ciprofloxacin, doxycycline,
and tetracycline (also purchased from Sigma-Aldrich) were prepared as 1-mg/ml
stocks dissolved in dimethyl sulfoxide or ethanol as directed by the manufacturer.
Working stocks of antibiotics consisted of freshly diluted antibiotics at concen-
trations of 64 mg/liter in USM. An adapted breakpoint analysis was used to
screen for the presence of resistant mutants within the 61 isolates. Although no
official breakpoint values are available for Ureaplasma, we determined the fol-
lowing values based on the normal ranges of MICs reported for Ureaplasma, as
stated in Cumitech 34 (36). As seen in Fig. 1, the bottom row of wells contained
2 mg/liter tetracycline, the next row up contained 4 mg/liter ciprofloxacin, the
second row contained 4 mg/liter erythromycin, and the top row did not contain
an antibiotic for a growth control. Two milliliters of USM was inoculated with
either growing or frozen Ureaplasma spp. the night before titration was to be
performed. Twenty microliters of this culture of unknown color-changing units
(CCU) was then added to each well from A1 to A4, and serial 10-fold dilutions
were performed from columns A to H. In this manner, the 96-well plate was
organized to investigate the susceptibility of three different strains to three
antibiotics per plate by repeating the layout for wells A5 to H8 and A9 to H12
as described above, but using different test strains of Ureaplasma. Plates were
sealed and incubated at 37°C in a humidified cell culture incubator with ambient
CO2 for 48 h, at which time color change within the growth control rows had
ceased. From the titration of the antibiotic-free row, it was possible to calculate
back through the titration from 1 CCU, the final well in which color change
occurred, to the recommended 104 CCUs. Any strain which showed growth in
antibiotic-containing media at this level was subsequently fully investigated using
the full-plate method (see below), with additional MIC determinations for the
macrolides clarithromycin and azithromycin for suspected erythromycin-resistant
isolates and doxycycline for suspected tetracycline-resistant isolates. SV9 (Van-
couver strain) was used as a positive control for tetracycline resistance; however,
no known characterized resistant strains were available to use as controls for
erythromycin and ciprofloxacin resistance. USM (with and without antibiotics)
was also incubated in the absence of added Ureaplasma spp. to serve as a
negative color-changing control. Validation of this technique was performed by
determining the antibiotic MICs for ATCC (American Type Culture Collection,
Bethesda, MD) isolates of Staphylococcus aureus (ATCC 29213), Enterococcus
faecalis (ATCC 29212), and Escherichia coli (ATCC 25922). MICs determined in
Mueller-Hinton medium for erythromycin, ciprofloxacin, and tetracycline were
within the accepted MIC ranges for these bacteria.
Modified broth microdilution technique for determination of antibiotic MICs.
In a 96-well plate, wells A1 to H1 received 360 l of 64 mg/liter antibiotic in
USM, and 180 l sterile USM was added to the remaining wells (A2 to H12) of
the plate. Using a multichannel pipette, rows of doubling dilutions were made by
transferring 180 l from row A1 to H11 (and an excess of 180 l was discarded
from row A11 to H11; see the instructional diagram in Fig. S1 in the supple-
mental material). Rows A12 to H12 remained free of antibiotic for unrestricted
growth comparison. Thus, an antibiotic gradient was created from 64 mg/liter to
0.0625 mg/liter for the antibiotic in question. Twenty microliters of Ureaplasma
from the overnight culture of unknown CCU was added to each well in the
columns A1 to A12 (1:10 dilution). A 10-fold dilution curve of bacteria was then
titrated at 90 degrees across the antibiotic gradient (i.e., A1 to -12 to H1 to -12).
Plates were sealed and incubated at 37°C in a humidified cell culture incubator
with ambient CO2 for 48 h, at which time color change within the growth control
had ceased (see Fig. 2). The MIC was defined as the lowest concentration of
antibiotic that prevented a color change after 48 h when read at 104 CCU
(relative to growth in the antibiotic-free medium). USM (with and without
antibiotics) was also incubated in the absence of added Ureaplasma isolates to
serve as a negative color-changing control.
Speciation of Ureaplasma isolates. Confirmation of Ureaplasma was deter-
mined by amplification of the Ureaplasma-specific urease gene (a 430-bp DNA
product) using Blanchard and coworkers’ (5) U4 and U5 primers (Table 1).
Clinical isolates were further separated into species based on PCR primers which
amplify a region of the multiple-banded antigen (MBA), as published by Teng et
al. (35), also listed in Table 1. Primer set UM-1 for Ureaplasma parvum yielded
a 403-bp product, with a 448-bp product for Ureaplasma urealyticum. For anti-
biotic-resistant U. parvum strains, SVs were determined by sequencing the UM-1
primer set amplicon and comparing SV-specific base compositions at nucleotides
54 to 56 and 82 to 84 (17, 35). Bacterial DNA from a 1.5-ml overnight
culture was released by boiling lysis (95°C for 10 min) following centrifugation at
13,000  g for 10 min, removal of all USM, and resuspension in 50 l sterile
water. A 20-l PCR (containing 1 GoTaq Flexi buffer [Promega], 1.5 mM
MgCl2, 0.2 mM deoxynucleoside triphosphates, 0.25 M each primer, and 1.25
units of GoTaq DNA polymerase) was performed on 1 l (as well as 1 l of a
1:100 dilution to lessen possible polymerase inhibitor concentrations) for 35
cycles using the annealing temperatures listed in Table 1. To determine the DNA
sequence, five 20-l PCRs were pooled and purified from other reaction com-
ponents using a Novagen SpinPrep PCR clean-up kit (Merck Chemicals Ltd.,
Nottingham, United Kingdom) per the manufacturer’s instructions and then
sequenced using the BigDye Terminator v3.1 cycle sequencing kit and analyzed
with an ABI Prism 3130xl genetic analyzer (Applied Biosystems, Warrington,
United Kingdom).
Amplification and sequence determination of putative resistance targets. For
erythromycin- and ciprofloxacin-resistant isolates, mutations in bacterial genes
previously associated with resistance (3, 22) were investigated.
DNA encoding bacterial 23S rRNA gene, L22, and L4 proteins was amplified
and sequenced for macrolide-resistant strains; gyrase subunits and topoisomer-
ase subunits were sequenced for ciprofloxacin-resistant strains, and tetM genes
from both tetracycline-susceptible and -resistant isolates were sequenced. PCR
primers and annealing temperatures are outlined in Table 1. Amplicons were
purified and sequenced as detailed above.
RESULTS
Species distribution among Ureaplasma isolates tested. Sev-
enty-five percent (15/20) of the archived UHW samples were
successfully revived from 80°C storage, while only 59.7%
(46/77) of archived HPA samples were successfully revived.
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This may reflect the relatively short storage time for the former
samples (less than 18 months) compared to that of the latter
samples (up to 4 years), although differences in isolate prepa-
ration prior to freezing them may have equally contributed.
For all 61 revived samples, 49 were found to belong to U.
parvum (80%) and 12 to U. urealyticum (20%). A minor dif-
ference in species distribution was identified between HPA
and UHW collections, but this was not deemed significant by
Fisher’s exact test analysis (78% U. parvum versus 87% U.
parvum, respectively).
Examples of breakpoint and detailed MIC determination.
Ninety-six-well plates were set out as detailed in Materials and
Methods for breakpoint screening of antibiotic resistance. An
example showing strains resistant to erythromycin, ciprofloxa-
cin, and tetracycline is shown in Fig. 1. Nonturbid, dark red
wells (which appear dark gray in the figure) are indicative of
positive Ureaplasma growth in the selective medium. If the last
well showing growth in the 10-fold dilution (in the top row,
lacking antibiotics) is considered to have 1 CCU, then four
columns to the left represents 103 CCU, and five columns to
the left represents 104 CCU (isolated by the dotted box). Fol-
lowing previously published recommendations that Urea-
plasma resistance needs to be assessed using an input of 104
CCU (36), resistance-to-threshold antibiotic concentrations (4
mg/liter erythromycin, 4 mg/liter ciprofloxacin, or 2 mg/liter
tetracycline) were identified by comparison of wells within the
dotted box. Figure 1 shows breakpoint identification of an
erythromycin-resistant clinical SV1 isolate (UHWO10; i.e.,
10th sample from UHW patient O) (Fig. 1, top), a ciprofloxa-
cin-resistant clinical SV1 isolate (HPA18; i.e., 18th HPA sam-
TABLE 1. Primers and conditionsa
Primers used for PCR amplification Primer sequence Annealingtemp (°C) Size (bp) Reference
Ureaplasma-specific urease gene primers
U4 5 ACGACGTCCATAAGCAACT 3 54 430 5
U5 5 CAATCTGCTCGTGAAGTATTAC 3
UM-1
UMS-125 5 GTATTTGCAATCTTTATATGTTTTCG 3 52 403 (U.p) 35
UMA226 5 CAGCTGATGTAAGTGCAGCATTAAATTC 3 448 (U.u)
Erythromycin resistance primers
23S OP1 domain V
MH23S-11 5 TAACTATAACGGTCCTAAGG 3 56 1,339 22
UP23S-OP1 5 ACCACCATTCAATGTTTGAC 3
23S OP2 domain V
MH23S-11 5 TAACTATAACGGTCCTAAGG 3 56 1,427 22
UP23S-OP2R2 5 CGTATACTTTGCCATAGTGTTGCC 3
L4
UPL4-U 5 TCTATTGATGGTAACTTCGC 3 60 392 22
UPL4-R 5 GTTGAAGGTGTTTCTAAATCGC 3
L22
UPL22-U 5 TTCGCACCGTAAAGCTTCTC 3 60 458 22
UPL22-R 5 GTTCTGGATCAACGTTTTCG 3
Tetracycline resistance primers
TetM primers for screening
TetMF 5 TTATCAACGGTTTATCAGG 3 48 397 4
TetMR 5 CGTATATATGCAAGACG 3
TetM primers for sequencing
TetMF-78 5 GTATACCTATGGTTATGC 3 48 901
TetMR 5 CGT ATA TAT GCA AGA CG 3*
TetMF 5 TTATCAACGGTTTATCAGG 3 54 1,715
TetMR 2123 5 GCATTTCGGACAATAGAGGGGG 3*
Ciprofloxacin resistance primers
GyrA
gyrA-1 5 TTGCTGCTTTCGAAAACGG 3 50 336 3
gyrA-2 5 CTGATGGTAAAACACTTGG 3
GyrB
gyrB-3 5 CCTGGTAAATTAGCTGACTG 3 55 310 3
gyrB-4 5 TTCGAATATGACTGCCATC 3
ParC
parC-5 5 ACGCAATGAGTGAATTAGG 3 55 309 3
parC-6 5 CACTATCATCAAAGTTTGGAC 3
ParE
parE-7 5 ATGGGCGGAAAATTAACGC 3 55 313 3
parE-8 5 CTTGGATGTGACTACCATCG 3
a PCR primers used for the amplification and sequencing of genes associated with resistance to respective antibiotics. Annealing temperatures and predicated product
sizes are indicated. U. p, U. parvum; U. u, U. urealyticum; , primers which were designed for this study.
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ple) (middle), and a tetracycline-resistant clinical SV6 isolate
(HPA23) (bottom). While we have used the 104 CCU column
to assess antibiotic resistance, using 103 CCU would be equally
valid, and no difference in our MICs was found when reading
either the 103 or 104 CCU column.
For those isolates identified by breakpoint analysis, MICs
for a single antibiotic were determined using a range of con-
centrations with a full-plate single antibiotic assay (Fig. 2).
Using the same method used for determining which column
contained 104 CCU (isolated by dotted box), examples of an
erythromycin-susceptible clinical isolate (HPA18; MIC, 1 mg/
liter) (Fig. 2A) and the highly resistant clinical isolate
(UHWO10; MIC, 64 mg/liter) (Fig. 2B) are shown.
Summary of MICs among resistant isolates. All isolates
were examined for resistance to erythromycin, ciprofloxacin,
and tetracycline with the resistant isolates summarized in Ta-
ble 2. Six isolates were identified to have an MIC greater than
the normal MIC range previously published in Cumitech 34
(0.02 to 4 mg/liter) (36), giving the isolates a prevalence of
9.8%, although only one of these isolates (UHWO10) is likely
to represent true antibiotic resistance with an MIC of 64
mg/liter. Among the erythromycin-resistant isolates, azithro-
mycin and clarithromycin MICs were comparable to those of
susceptible controls, with the exception of the highly resistant
UHWO10, which was additionally resistant to clarithromycin
(MIC  4 mg/liter) but susceptible to azithromycin (normal
MIC ranges, 0.5 to 4 mg/liter for azithromycin and 	0.004 to
2 mg/liter for clarithromycin) (36). A single tetracycline-resis-
tant clinical isolate, HPA23, was identified with tetracycline
and doxycycline MICs of 64 and 16 mg/liter, respectively (1.6%
prevalence). A single ciprofloxacin-resistant clinical isolate,
HPA18, was also identified with an MIC of 8 mg/liter (1.6%
prevalence).
Molecular characterization of macrolide resistance. Muta-
tions in the 23S rRNA genes (two separate operons) and as-
sociated L4 or L22 protein from the prokaryotic ribosomal
complex have previously been reported to be associated with
macrolide resistance (22). These genes were sequenced from
the highly resistant clinical isolate UHWO10 as well as the five
isolates with an erythromycin MIC of 8 mg/liter and a selection
of the susceptible isolates. No mutations were found in either
the 23S rRNA operon or the L22-encoding gene of any of the
isolates; however, a 6-bp deletion was identified in the L4
protein gene from the highly resistant UHWO10. This in-
frame deletion resulted in the loss of arginine and glutamine
residues at residue numbers 66 and 67, respectively
(
R66Q67) (Table 3). This region was sequenced in clinical
isolates representing susceptible SV1 strains (representing an
SV control) and other U. parvum strains. All were identical to
the published SV3 genome sequence (accession number
AF222894) (12). Furthermore, this region was also conserved
in the SV8 reference strain and a U. urealyticum clinical strain
(Table 3). Comparison of all sequences found three species-
specific conserved nucleotide polymorphisms (all silent) in the
L4 protein gene (U. parvum T309, G357, and C373 compared
to U. urealyticum C309, A357, and T373). While 80% of all
isolates were found to belong to U. parvum, four out of five of
the isolates with MICs of 8 mg/liter belonged to U. urealyticum.
FIG. 1. Photographs of antibiotic breakpoint investigation showing
an erythromycin (Erythro)-resistant strain (UHWO10) (A), a cipro-
floxacin (Cipro)-resistant strain (HPA18) (B), and a tetracycline (Tet)-
resistant strain (HPA23) (C). Dark red wells indicating growth of
ureaplasma appear dark gray, while orange-yellow wells representing
no ureaplasma growth appear light gray in the grayscale photograph.
Columns containing 104 CCU are identified by a dotted box, and
comparison of growth in the absence of antibiotics (control) was used
to determine resistance to 4 mg/liter erythromycin, 4 mg/liter cipro-
floxacin, or 2 mg/liter tetracycline.
FIG. 2. Full-plate determination of MIC for erythromycin for a
susceptible SV1 isolate (A) and a resistant (UHWO10) isolate (B) in
plates containing a gradient of antibiotic from 64 mg/liter to 0.06
mg/liter. Dark red wells indicating growth of ureaplasma appear dark
gray, while orange-yellow wells representing no ureaplasma growth
appear light gray in the grayscale photograph. Columns representing
104 CCU growth in the absence of antibiotic are shown by the dotted
box, and for the susceptible strain, a circle shows the first concentration
of erythromycin to inhibit growth (MIC  1 mg/liter). Since the resis-
tant isolate (UHWO10) grew even in the presence of 64 mg/liter
erythromycin, the MIC is determined to be 64 mg/liter.
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Therefore, 33% of the all U. urealyticum isolates identified
were found to be less susceptible to erythromycin (but suscep-
tible to clarithromycin and azithromycin) (Table 2).
Molecular characterization of tetracycline resistance. Tet-
racycline-resistant bacterial strains are often found to have the
transferable tetM genetic element encoded in their genome.
The SV9 (Vancouver) reference strain, known to contain the
tetM gene (25), demonstrated a tetracycline-resistant (Tetr)
phenotype, with tetracycline and doxycycline MICs of 64
mg/liter and 64 mg/liter, respectively. Only one U. parvum
clinical isolate (HPA23) was found to be Tetr and doxycycline
resistant (Table 2), coincident with the identification of the
tetM gene by PCR (data not shown). PCR screening of all 61
isolates identified a tetM-positive U. urealyticum clinical isolate
(HPA6) that was susceptible to both tetracycline and doxycy-
cline (Table 2). The entire tetM gene was sequenced and com-
pared to resistant strains SV9 (Vancouver) and HPA23 and
susceptible strain HPA6 (Table 3). No mutations in the coding
region of the tetM gene were found for HPA6 that could
account for the inability of a resultant protein to mediate
tetracycline resistance, nor was any alteration to the endoge-
nous tetM gene promoter found that may have stopped TetM
protein expression. Therefore, we have no explanation for the
susceptibility of this tetM-positive isolate. Interestingly, three
amino acid polymorphisms (H209Q, V216L, N223S) were
found in HPA23 that did not affect function and were identical
to those originally reported for a Tetr strain isolated in Seattle,
Washington, in 1984 (Table 3) (28).
Molecular characterization of ciprofloxacin resistance. A
single ciprofloxacin-resistant (Cipr) clinical isolate, HPA18,
was identified with an MIC of 8 mg/liter. Mutations in the
subunits of the bacterial gyrase (gyrA and gyrB) and topoisom-
erase IV (parC and parE) genes, known as the quinolone re-
sistance-determining regions, have previously been associated
with resistance to other fluoroquinolone antibiotics (2, 3, 10,
11, 41, 42). The sequences of these genes were determined
from the Cipr HPA18 isolate and several susceptible clinical
isolates and compared to both known SV reference strains and
the published SV3 sequence (12). A single base pair change at
position 244 (G244A) in the parC gene was identified (Table
3), resulting in a codon change and subsequent substitution of
aspartic acid for asparagine (D82N) relative to those of other
U. parvum sequences from susceptible controls from both
species.
DISCUSSION
Summary of mutations found. This study describes a mod-
ified breakpoint analysis used to screen for antibiotic resistance
among a large number of clinical Ureaplasma samples of un-
known initial CCU titration. U. parvum strains resistant to
ciprofloxacin and tetracycline as well as one highly erythromy-
cin-resistant strain were identified. The species of all clinical
isolates were determined by PCR analysis of the gene encoding
the MBA protein, and in many cases, the SV was determined
through analysis of the amplicon sequence in this region. Po-
TABLE 2. MICs for resistant and control U. parvum and U. urealyticum strains
Isolate Species (SV)
MICs with indicated antibioticsa
Ery Azi Cla Tet Dox Cip
HPA3 U. urealyticum 4 0.5 	0.125 2 0.5 4
HPA6 U. urealyticum 8 	0.25 	0.125 2 0.5 4
HPA12 U. urealyticum 8 	0.25 	0.125 2 0.5 4
HPA17 U. urealyticum 8 0.5 	0.125 1 0.25 4
HPA18 U. parvum (SV1) 4 	0.25 	0.125 2 0.25 8
HPA20 U. urealyticum 8 	0.25 	0.125 2 0.5 4
HPA23 U. parvum (SV6) 4 	0.25 	0.125 64 16 	2
HPA32 U. parvum (SV14) 8 	0.25 	0.125 1 0.25 	2
UHWJM U. parvum 4 	0.25 	0.125 2 0.5 4
UHWO10 U. parvum (SV1) >64 2 4 1 0.25 4
UHWP2 U. parvum 4 	0.25 	0.125 2 0.5 4
UHWQ3 U. parvum (SV1) 4 	0.25 	0.125 1 0.25 4
a MIC results from a selection of resistant isolates (in boldface) and susceptible isolates, as determined by growth comparison at 104 CCU. Ery, erythromycin; Azi,
azithromycin; Cla, clarithromycin; Tet, tetracycline; Dox, doxycycline; Cip, ciprofloxacin.
TABLE 3. Partial protein sequence alignments of antibiotic-
resistant and -susceptible isolates
Isolate tested with
indicated antibiotica Sequence
b
Erythromycin
L4 isolates
SV3s .......................................63KPWRQKHT70
UHWO10r.............................63KPW – – KHT70
Tetracycline
TetM isolates
SV9 Seattler ..........................209HNCSLFPVYHGSAKNNIGID228
HPA23r..................................209HNCSLFPVYHGSAKNNIGID228
HPA6s....................................209QNCSLFPLYHGSAKSNIGID228
SV9 Vancouverr ...................209QNCSLFPLYHGSAKSNIGID228
Fluoroquinolone
ParC isolates
Consensuss ............................78HPHGDSSIYE87
HPA18r..................................78HPHGNSSIYE87
Bebear UUg2-5r...................78HPHGDLSIYE87
Bebear UUcr ........................78HPHGDSSIYK87
a Superscript letters (r and s) indicate resistance and susceptibility, respec-
tively, to the indicated antibiotics.
b Boldfaced amino acids identify areas of sequence divergence within a vari-
able region of the protein. The sequence of TetM of the Vancouver strain was
determined at the UHW. Underlined amino acids identify areas of sequence
divergence relative to the sequences of susceptible strains. Previous S83L amino
acid substitutions arising from mutation and E87K substitutions associated with
resistance as described by Bebear et al. (2) are also shown. –, deletion of amino
acids R and Q.
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tential underlying molecular mechanisms of antibiotic resis-
tance were investigated, based on target genes identified by
previous investigators. A unique deletion of 
R66Q67 was
identified in the L4 protein of the bacterial 50S ribosomal
complex in an isolate with high erythromycin resistance, a
unique point mutation of D82N in the ParC subunit of bacte-
rial topoisomerase in the ciprofloxacin-resistant isolate, and
the presence of the tetM element in the tetracycline-resistant
isolate.
Advantages of the breakpoint method. The primary advan-
tage to using the modified breakpoint methodology described
here is the simultaneous determination of input inoculum for
determination of susceptibility at the 104 CCU inoculum. Us-
ing this methodology, the investigator also has the option of
determining the amount of CCU reduction at a defined anti-
biotic concentration. By defining the final well in which color
change occurred in the growth control as 1 CCU, comparison
of growth in the column representing an initial inoculum of 104
CCU (as indicated in Fig. 1) identifies resistant organisms to
be further interrogated by the full-plate, single-antibiotic
method. As seen in Fig. 1, the presence of a resistant isolate is
readily noticeable: 10-fold reduction (or less) in growth was
observed at a 2 or 4 mg/liter concentration of antibiotic. Fur-
ther investigation with the full-plate method found that less
than 10-fold reduction in growth was seen for UHWO10 when
grown in up to 64 mg/liter erythromycin (Fig. 2).
Ciprofloxacin resistance. Ciprofloxacin was used as a repre-
sentative of the bactericidal fluoroquinolone antibiotic family
that targets two bacterial topoisomerases, namely topoisomer-
ase IV and DNA gyrase. Numerous mechanisms have been
described by which bacteria can mediate resistance to fluoro-
quinolones, including mutation of the topoisomerase genes,
decreased membrane permeability, active drug efflux, modifi-
cation by a fluoroquinolone-inactivating enzyme, or the pres-
ence of a Qnr protein (27). We have identified a point muta-
tion leading to an amino acid substitution which was two amino
acids downstream from the proposed active site of the ParC
protein (20). Six separate groups have investigated a total of 32
resistant isolates and reported mutations in Ureaplasma genes
associated with fluoroquinolone resistance (2, 3, 10, 11, 41, 42).
Nineteen of 32 fluoroquinolone-resistant strains investigated
by these groups have the same mutation in the parC gene, S83L
(or S80L, if using homology to the E. coli position to identify
the location) (Table 3); furthermore, similar mutations in ParC
have been found in fluoroquinolone-resistant S. aureus and
Streptococcus pneumoniae, which are reported to have MICs
similar to those of resistant Ureaplasma strains (15). The mu-
tation in the Cipr isolate D82N is adjacent to this region, and
this isolate has a ciprofloxacin MIC similar to that of isolate
UUc identified by Bebear et al. (2), who also found an E87K
mutation in the near vicinity, indicating this is a dominant
target for fluoroquinolone resistance. (Table 3).
Erythromycin resistance. This investigation also identified
one highly resistant erythromycin resistant isolate (MIC, 64
mg/liter); however, five additional isolates each consistently
showed an MIC of 8 mg/liter, which is higher than the range of
0.02 to 4 mg/liter listed in the Cumitech 34 reference manual
(36). Interestingly, 4/5 of the less susceptible isolates were U.
urealyticum, which represented 33% of the total U. urealyticum
isolates screened, suggesting a possible inherently increased
tolerance of U. urealyticum isolates to erythromycin relative to
that of U. parvum isolates. There is much less information
available about the mechanism of erythromycin resistance in
Ureaplasma spp. In fact, this is the first full molecular charac-
terization of a clinical Ureaplasma isolate with erythromycin
resistance. The physiological mechanism of erythromycin re-
sistance was first indicated by Palu et al. (21) almost 20 years
ago, who demonstrated reduced radiolabeled erythromycin
binding to ribosomes of resistant Ureaplasma compared to that
of a susceptible strain. However, technical advances since that
report have greatly enhanced the ability to investigate molec-
ular mechanisms. Investigation of other macrolide-resistant
bacteria has identified mutations that inhibit erythromycin
binding to the bacterial 50S ribosomal complex, where it ex-
hibits bacteriostatic activity through inhibition of protein syn-
thesis. Pereyre et al. serially passaged a U. parvum reference
strain 45 to 50 times in increasing amounts of erythromycin
and sequenced associated genes: two 23S rRNA operons and
L4 and L22 ribosome-associated proteins (22). They consis-
tently found mutation of the erythromycin-binding site around
nucleotide position 2067 (2058 numbering based on homology
to E. coli) near the peptidyl transferase loop in domain V of
one of the 23S rRNA operons and occasionally found addi-
tional mutation of the associated L4 or L22 protein. Dongya et
al. identified a number of point mutations within the 23S
rRNA of 18 clinical isolates with various degrees of resistance
to the macrolides josamycin, clarithromycin, roxithromycin,
and azithromycin; however, they did not investigate resistance
to erythromycin (9). Interestingly, none of the mutations de-
scribed were in the region of nucleotide 2067. Our investiga-
tion did not find mutations in either the 23S rRNA operon or
the L22 protein but did detect a deletion of two adjacent amino
acids in the L4 protein for the highly resistant strain (MIC,
64 mg/liter). No mutations were found in the isolates with an
erythromycin MIC of 8 mg/liter, yet compensating mutations
outside of the investigated regions, DNA methylation, expres-
sion of bacterial proteins that modify macrolides, or increased
drug efflux via ion channels may have been responsible for the
relative increase in tolerance to erythromycin for these strains.
Kenny and Cartwright previously showed that susceptibility to
erythromycin was reduced in acidic growth medium; however,
medium pH had to fall below 6.5 before an effect was observed
(16). As our USM had a pH of 6.65, the MICs were determined
relative to each other in the same batch of USM, and the
findings were consistent upon repeated testing. As a result, we
do not feel that the reduced susceptibility of these five isolates
was due to a pH artifact for the USM used.
Mutations within the highly conserved region of L4 have
previously been noted in both laboratory-derived and clinically
isolated macrolide-resistant pneumococci and E. coli strains (6,
32, 33). Both a substitution mutation (G69C) and an insertion
mutation (6-bp insertion between the codons encoding Q67
and K68) were found in two resistant pneumococcus strains
(32, 33). Clinical isolates found by the same group made up a
distinct clonal cluster which contained a substitution from
69GTG71 to 69TPS71 as well as one isolate which contained a
6-amino-acid insertion within the same region (33). A similar
mutation (K63E) within L4 of E. coli has also been found to be
associated with resistance to erythromycin (6) and was located
adjacent to the deletion described here. The resultant three-
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dimensional alteration to the entire ribosomal complex as a
result of the structural L4 mutation must prevent the interaction
of the C5 sugar of the macrolide with the residues around A2067
(A2058 E. coli numbering) and abrogate the ability of erythromy-
cin to inhibit protein synthesis in the resistant strain (23).
Tetracycline resistance. Currently, the only known mecha-
nism of tetracycline resistance for mollicutes is the presence of
the tetM-transferable genetic element. It was first described in
Ureaplasma by Roberts and Kenny in 1986 (24) and has been
the focus of investigations by several groups since then. Unlike
the studies by Robertson et al. (26), who found that all 26 of
their Tetr isolates were also resistant to erythromycin at or
above 2 mg/liter, our control SV9 Tetr and clinical Tetr isolates
were susceptible to erythromycin (MIC, 4 mg/liter). Blanchard
et al. (4) have previously shown that screening Ureaplasma
isolates by PCR readily identified Tetr strains. However, we
found a tetracycline-susceptible strain (HPA6) that screened
tetM positive with these strains. Recently, Degrange et al. iden-
tified two tetM-positive Mycoplasma hominis isolates that were
tetracycline susceptible (8). One of these M. hominis isolates
had a 1,260-bp insertion in the leader peptide sequence (likely
preventing successful transcription), while no mutations were
found within the tetM gene or promoter region of the second
isolate. Like the latter case for our Tets tetM HPA6 strain, we
could find no explanation for the susceptibility when compar-
ing the sequence to that of the control Tetr SV9 (Vancouver)
strain. We also found that our Tetr strains were resistant to
both tetracycline and doxycycline, which is in contrast with the
findings of Blanchard et al. (4). They identified 21 clinical Tetr
Ureaplasma isolates and found that 8 were resistant to doxy-
cycline, 2 were intermediate, and 11 were susceptible. It has
been proposed that doxycycline is less of an inducer of tetM
transcription in some organisms than tetracycline. In this study,
we demonstrated that our clinical tetracycline-resistant isolate
HPA23, which harbored a functional TetM protein, was addi-
tionally resistant to doxycycline.
Conclusion. In conclusion, we have developed a reliable
method to determine antimicrobial susceptibility of Urea-
plasma isolates without prior knowledge of inoculum size. Al-
though this is the second molecular investigation of macrolide
resistance in clinical Ureaplasma isolates, more erythromycin-
resistant strains are required to determine the prevalence of
mutations in the relevant genes associated with resistance.
Screening for the tetM gene could identify tetracycline-resis-
tant strains; however, we found one false-positive strain, which
raises a note of caution for the use of PCR screening for
antibiotic resistance. It appears that mutation within an 8-
amino-acid region of topoisomerase IV parC is commonly
found in fluoroquinolone-resistant Ureaplasma, with S83L be-
ing the dominant mutation, but molecular screening methods
would have to employ more-complex methods, such as capil-
lary electrophoresis-based single-strand conformation poly-
morphism, to screen for all potential mutations.
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